HC Wainwright Reiterates “Buy” Rating for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals (NASDAQ:CPRX)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $35.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 59.26% from the company’s previous close.

Several other research analysts have also weighed in on CPRX. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Bank of America reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Truist Financial lifted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Robert W. Baird initiated coverage on shares of Catalyst Pharmaceuticals in a report on Tuesday, February 4th. They issued an “outperform” rating and a $28.00 target price on the stock. Finally, Stephens reissued an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $21.98 on Friday. The business has a 50 day moving average price of $22.21 and a two-hundred day moving average price of $21.40. Catalyst Pharmaceuticals has a 1-year low of $14.47 and a 1-year high of $24.64. The company has a market capitalization of $2.62 billion, a price-to-earnings ratio of 18.58, a price-to-earnings-growth ratio of 3.31 and a beta of 0.80.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares in the company, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Large investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC bought a new stake in Catalyst Pharmaceuticals during the fourth quarter worth $27,000. Farther Finance Advisors LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 1,495 shares during the period. Larson Financial Group LLC grew its position in shares of Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 2,994 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Catalyst Pharmaceuticals during the fourth quarter worth approximately $65,000. Finally, KBC Group NV lifted its holdings in Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,542 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.